Company · Healthcare
Piramal Pharma.
PublicTracked across 1 covered firm · 1 equity · 0 creditVintage Sep 2026Healthcare sector dossier →
Equity holders · 1
| Firm | Entered | Entry | Status | 12-mo | Read |
|---|---|---|---|---|---|
| Carlyle | 2020 | 20% strategic growth (₹3,523 Cr / ~$490M) via CA Alchemy Investments | Public | → | Down to 18% by Mar 2025; a planned 6-10% block sale (₹1,750-2,700 Cr, Motilal Oswal-mandated) was reported Jul 2025, then cancelled Aug 2026 with no reason given — sources conflict on whether the stake is back at 20% or still 18% |
Aggregated from Gravitywell's tracked position books: covered firms only, not the full cap table. Entries, stages and reads are per-holder reconstructions from public disclosures (E). Point-in-time as of Sep 2026.
Stay ahead